Table 46: Patient Characteristics. Transurethral Microwave Thermotherapy (TUMT) Versus TURP.
| Study, Year | Patients, No. (Treatment, control) | Inclusion criteria | Prostate size Mean (SD), mL | Mean follow-up Years (months where specified) | Equipment and software | No. available for follow-up |
|---|---|---|---|---|---|---|
| Wagrell, et al. 2004 & 2002 (76;79) (Multicentre trial) |
146 (100, 46) |
Symptomatic BPH, prostate size 30–100cm3; IPSS≥13; Qmax < 13mL/s | TUMT: 48.9 (15.8) TURP: 52.7 (17.3) |
3 | ProstaLund Feedback Treatment (PLFT) using Core Therm device |
3 years TUMT: IPSS: 68; QoL: 68; Qmax: 66; PVR: 68 TURP: IPSS: 35; QoL: 35; Qmax:34; PVR: 34 |
| Norby et al. 2002 (56) 3-arm study (multicentre) |
70 (46, 24) 3 of the control group received TUIP rather than TURP Third arm: contacle laser: 48 |
Patients with BPH 50 years or older; IPSS ≥ 7; QOL ≥3; Qmax <12 mL/s | TUMT: 43 TURP: 44 |
6 months | Prostatron system | TUMT: 44 TURP: 22 |
| Floratos et al. 2001 | 144 TUMT: 78 TURP: 66 |
Patients with BPH 45 years or older; LUTS > 3 months; Prostate volume ≥30 cm3; Prostatic urethral length ≥25 mm; Madsen symptom score ≥ 8; Qmax ≤ 15 mL/s; PVR≤350 mL | TUMT: 42 (30–82) TURP: 48 (31–84) |
TUMT: 32.4 TURP: 33.7 Months |
Prostatron system |
3 years TUMT IPSS:36; QOL: 36; Qmax: 27; PVR: 27 TURP IPSS: 32; QOL: 32; Qmax: 29; PVR: 29 |
| Francisca et al. 2000 | 147 TUMT: 74 TURP: 73 |
≥ 45 years; Prostate volume ≥ 30 cm3; Prostatic urethral length ≥ 25 mm; Madsen symptom score ≥8; Qmax ≤15 mL/s; postvoid residual ≤350 mL | TUMT: 50 (19.4) TURP: 52 (19.2) P =.70 |
1 | Prostatron system |
TUMT IPSS: 48; Qmax: 49; PVR: 47; Madsen: 38 TURP IPSS: 39 Qmax: 37 PVR: 38 Madsen: 35 |
BPH refers to benign prostatic hyperplasia; IPSS, International Prostate Symptom Score; LUTS, Lower urinary tract symptoms; PVR, postvoid residual urine; Qmax, maximum flow rate; QOL, Quality of life; TUIP, transurethral incision of the prostate; TUMT, transurethral microwave thermotherapy; TURP transurethral resection of the prostate